Who is sponsoring NCT05363800?

NCT05363800 is sponsored by Jiangsu HengRui Medicine Co., Ltd..

What drugs are being tested in NCT05363800?

Interventions in NCT05363800: HRS-3738.

Is NCT05363800 still recruiting?

NCT05363800 is currently status unknown. Last updated 29 July 2022.

Last reviewed 2022-07-29 · How we verify

NCT05363800

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma

Status unknown Phase 1 Last updated 29 July 2022

What this trial tests

Phase 1 trial testing HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma in 198 participants. Status unknown.

Timeline

17 June 2022

Primary endpoint
30 October 2024

30 December 2024

Quick facts

Lead sponsor	Jiangsu HengRui Medicine Co., Ltd.
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	198
Start date	17 June 2022
Primary completion	30 October 2024
Estimated completion	30 December 2024
Sites	3 locations across China

Drugs / interventions tested

HRS-3738 — full drug profile →

Conditions studied

Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma — all drugs for Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma →

Sponsor

Jiangsu HengRui Medicine Co., Ltd. — full company profile →

Who can join

18 and older, any sex, with Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of HRS-3738 in patients with recurrent and refractory Non-Hodgkin's lymphoma and multiple myeloma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Jiangsu HengRui Medicine Co., Ltd. trials

Trials by the same sponsor.

NCT07252921 — Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation in Adults · Phase 2 · completed
NCT07142850 — A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Bolus and Infusion HR · Phase 1 · completed
NCT07073157 — Effect of HRS-8427 for Injection on the Pharmacokinetics of Furosemide and Metformin in Healthy Subjects。 · Phase 1 · completed
NCT07076459 — A Comparative Pharmacokinetic Study of Single-Dose Administration of HR091506 Tablets From Different Batches in Healthy · Phase 1 · completed
NCT07049107 — Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05363800 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jiangsu HengRui Medicine Co., Ltd.
Last refreshed: 29 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05363800.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing